Abstract
Abstract
Objective
Inclusion body myositis (IBM) has an unclear molecular etiology exhibiting both characteristic inflammatory T-cell activity and rimmed-vacuolar degeneration of muscle fibers. Using in-depth gene expression and splicing studies, we aimed at understanding the different components of the molecular pathomechanisms in IBM.
Methods
We performed RNA-seq on RNA extracted from skeletal muscle biopsies of clinically and histopathologically defined IBM (n = 24), tibial muscular dystrophy (n = 6), and histopathologically normal group (n = 9). In a comprehensive transcriptomics analysis, we analyzed the differential gene expression, differential splicing and exon usage, downstream pathway analysis, and the interplay between coding and non-coding RNAs (micro RNAs and long non-coding RNAs).
Results
We observe dysregulation of genes involved in calcium homeostasis, particularly affecting the T-cell activity and regulation, causing disturbed Ca2+-induced apoptotic pathways of T cells in IBM muscles. Additionally, LCK/p56, which is an essential gene in regulating the fate of T-cell apoptosis, shows increased expression and altered splicing usage in IBM muscles.
Interpretation
Our analysis provides a novel understanding of the molecular mechanisms in IBM by showing a detailed dysregulation of genes involved in calcium homeostasis and its effect on T-cell functioning in IBM muscles. Loss of T-cell regulation is hypothesized to be involved in the consistent observation of no response to immune therapies in IBM patients. Our results show that loss of apoptotic control of cytotoxic T cells could indeed be one component of their abnormal cytolytic activity in IBM muscles.
Funder
Samfundet Folkhälsan
Helsingin Yliopisto
Biomedicum Helsinki-säätiö
Päivikki ja Sakari Sohlbergin Säätiö
Finska Läkaresällskapet
Suomen Lääketieteen Säätiö
Paulon Säätiö
Jane ja Aatos Erkon Säätiö
Sigrid Juséliuksen Säätiö
University of Helsinki including Helsinki University Central Hospital
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference50 articles.
1. Ikenaga C, Kubota A, Kadoya M et al (2017) Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology 89:1060–1068. https://doi.org/10.1212/WNL.0000000000004333
2. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323–327. https://doi.org/10.1212/wnl.56.3.323
3. Cai H, Yabe I, Sato K et al (2012) Clinical, pathological, and genetic mutation analysis of sporadic inclusion body myositis in Japanese people. J Neurol 259:1913–1922. https://doi.org/10.1007/s00415-012-6439-0
4. Askanas V, Engel WK (2005) Sporadic inclusion-body myositis: a proposed key pathogenetic role of the abnormalities of the ubiquitin-proteasome system, and protein misfolding and aggregation. Acta Myol 24:17–24
5. Askanas V, Engel WK (1998) Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol 10:530–542. https://doi.org/10.1097/00002281-199811000-00005
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献